- Home
- MUR vs KNSA Comparison
MUR vs KNSA Comparison
Compare MUR & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MUR | KNSA |
|---|---|---|
| Founded | 1950 | 2015 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.7B | 4.9B |
| IPO Year | 1994 | 2018 |
Fundamental Metrics
Financial Performance| Metric | MUR | KNSA |
|---|---|---|
| Price | $42.42 | $80.67 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 17 | 8 |
| Target Price | $41.53 | ★ $98.00 |
| AVG Volume (30 Days) | ★ 1.5M | 512.7K |
| Earning Date | 11-04-2026 | 11-03-2026 |
| Dividend Yield | ★ 3.26% | N/A |
| EPS Growth | N/A | ★ 225.00 |
| EPS | ★ 1.95 | 0.27 |
| Revenue | ★ $2,718,823,000.00 | $677,564,000.00 |
| Revenue This Year | $24.02 | $46.76 |
| Revenue Next Year | N/A | $22.90 |
| P/E Ratio | ★ $22.04 | $295.37 |
| Revenue Growth | N/A | ★ 60.09 |
| 52 Week Low | $26.49 | $35.53 |
| 52 Week High | $43.63 | $84.06 |
Technical Indicators
Market Signals| Indicator | MUR | KNSA |
|---|---|---|
| Relative Strength Index (RSI) | 67.38 | 56.25 |
| Support Level | $35.63 | $73.81 |
| Resistance Level | $42.88 | $81.42 |
| Average True Range (ATR) | 1.37 | 3.01 |
| MACD | 0.46 | 0.27 |
| Stochastic Oscillator | 82.15 | 64.09 |
Price Performance
Historical ComparisonAbout MUR Murphy Oil Corporation
Murphy Oil Corp is an oil and gas exploration and production company, with both onshore and offshore operations and properties. It operates in two geographic reportable segments the United States and Canada. It generates the majority of its revenue form the United States. The company also generates revenue from sales of oil and natural gas production activities.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.